Stock Taper 
BLLN
$95.03
▼ DOWN 0.25% (-0.24)
KEY STATISTICS
Market Cap$4.37 B
52w High$150.44
52w Low$61.96
Dividend Yield—
Frequency—
P/E135.76
Volume588.73K
Shares Out.46.00M
COMPANY
LEADERSHIP
CHIEF EXECUTIVE
Oguzhan Atay
ABOUT
SECTOR
Healthcare
WENT PUBLIC
November 6, 2025
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
713
PRICE TARGET
Target High$130.00
Target Low$125.00
Target Median$127.50
Target Consensus$127.50
UPCOMING EARNINGS
DateOct 6, 2026
DayTuesday
Rev. Est.$116.30M
OCT
6
TUE
PRICE
$95.03 ▼ DOWN 0.25% (−$0.24)About BillionToOne, Inc.
https://www.billiontoone.com ↗BillionToOne, Inc. is a precision diagnostics company developing molecular counting platforms for non-invasive prenatal screening, liquid biopsies, and cancer monitoring.
INDUSTRY
Medical - Diagnostics & Research
A PRODUCT BILLIONTOONE, INC. IS KNOWN FOR
Northstar Select
A liquid biopsy test analyzes blood samples to detect actionable tumor DNA mutations, enabling personalized cancer therapy decisions for patients with advanced solid tumors.
ETFS HOLDING THIS STOCK
ETFS HOLDING
51
LISTED HERE
17
RANKED BY POSITION SIZE
INSTITUTIONAL OWNERSHIP
SHARES OWNED
16.68%
HOLDERS
111
TOP 12 OF 111 · RANKED BY POSITION SIZE
Adams Street Partners LLC
Baillie Gifford & Co
Bamco Inc /Ny/
Price T Rowe Associates Inc /Md/
Neuberger Berman Group LLC
Nvp Associates, LLC
Invesco Ltd.
Jpmorgan Chase & Co
Wasatch Advisors LP
Vanguard Group Inc
Ubs Asset Management Americas Inc
Emerald Advisers, LLC
RATINGS SNAPSHOT
Overall rating: B-
Discounted Cash Flow4
Return On Equity3
Return On Assets4
Debt To Equity2
Price To Earnings1
Price To Book1
Overall Score3
MOST RECENT ANALYST GRADES
GRADE SUMMARY
BUY 2
OVERWEIGHT 1
EQUAL WEIGHT 1
4 GRADES IN THE LAST 12 MONTHS
